Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
It includes extensive molecular simulations of the receptor in its native membrane environment and the ensemble virtual screening accounting for its conformational mobility. In the case of dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets are determined on and between the subunits to cover the whole spectrum of possible mechanisms of action.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P18089
UPID:
ADA2B_HUMAN
Alternative names:
Alpha-2 adrenergic receptor subtype C2; Alpha-2B adrenoreceptor
Alternative UPACC:
P18089; A2RUS0; Q4TUH9; Q53RF2; Q9BZK0
Background:
The Alpha-2B adrenergic receptor, also known as Alpha-2 adrenergic receptor subtype C2, plays a pivotal role in mediating the catecholamine-induced inhibition of adenylate cyclase via G proteins. This receptor's affinity for various agonists and antagonists is well-characterized, with clonidine and yohimbine leading their respective categories.
Therapeutic significance:
Linked to Epilepsy, familial adult myoclonic, 2 (FAME2), the Alpha-2B adrenergic receptor's involvement in neurological disorders underscores its potential as a therapeutic target. Understanding its role could pave the way for innovative treatments for epilepsy and related cognitive impairments.